tbuckley/cabot-search huggingface dataset:
1095-201 QRS duration and depolarization heterogeneity in tetralogy of fallot patients before and after surgical repair of the pulmonary valve
Authors: Cees A Swenne, Bart Hooft van Huysduynen, Arie C Maan, Hedde Van de Vooren, Martin J Schalij, Ernst E Van der Wall, Henk J Ritsema van Eck, Albert De Roos, Mark G Hazenkamp, Alexander Van Straten, Hubert W Vliegen
Journal: Journal of the American College of Cardiology (2004)
Acute palmoplantar pustulosis
Authors: S.M. BURGE, T.J. RYAN
Journal: British Journal of Dermatology (1985)

Journal Article Acute palmoplantar pustulosis Get access S.M. BURGE, S.M. BURGE Department of Dermatology, The Slade Hospital, Oxford, U.K. Dr S.M.Burge, Department of Dermatology, The Slade Hospital, Headington, Oxford, U.K. Search for other works by this author on: Oxford Academic Google Scholar T.J. RYAN T.J. RYAN Department of Dermatology, The Slade Hospital, Oxford, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 113, Issue 1, 1 July 1985, Pages 77–83, https://doi.org/10.1111/j.1365-2133.1985.tb02046.x Published: 01 July 1985 Article history Accepted: 15 December 1984 Published: 01 July 1985
Abstract LB-426: Potent inhibitors of RAS pathways that bind directly to Ras proteins
Authors: Liv Johannessen, Jarrett R. Remsberg, Alla Ivanova, Vadim Gaponenko, Lyuba Khavrutskii, Sergey G. Tarasov, Michael Dean, Joseph Kates, Nadya I. Tarasova
Journal: Cancer Research (2012)

Abstract RAS genes are the most frequently mutated oncogenes in human cancer. Although they are believed to be among the most important drug targets in oncology, no synthetic molecules that directly target any member of the family and inhibit its function with appreciable in vivo or even in vitro activity have been identified. We have utilized a previously developed approach of peptide structural stabilization by membrane anchoring for the development of potent inhibitors of Ras proteins. We have tested lipopeptide analogs of different parts of Ras proteins and their interaction partners and have found lipopeptide analogs of hypervariable regions and of the C-terminal alpha helix (helix 6) of Ras proteins to be the most effective in interfering with Ras function and inhibiting Ras-dependent, but not Ras-independent growth of cancer cells. Direct binding of inhibitors to recombinant K-Ras (1-166) was detected by Microscale Thermophoresis (MST), and circular dichroism spectroscopy. NMR titration data revealed a localized interaction of helix 6 analogs with the Switch I region of K-Ras with the most significant chemical shift perturbations found in residues Q25, N26, S32, T35, and E37. Compounds inhibit the formation of active RasGTP and prevent Ras signaling to downstream effectors. Structural optimization of helix 6 analogs resulted in a metabolically stable, 12 amino acid residues long peptide made of all-D amino acids that inhibited the growth Ras-dependent cancer cell lines with GI50 below 1 nM. MST studies have shown that a fluorescently-labeled version of the compound binds to recombinant GDP-loaded K-Ras (1-166) with KD= 86 ±8 nM. Derivatives of K-Ras4B hypervariable region exert their activity by a significantly different mechanism: they cause degradation of Ras protein. Partially optimized compound of the series inhibit growth of cancer cells with GI 50 in submicromolar range and bind to recombinant K-Ras (1-166) with KD=1250±140nM (as determined in MST assay). CD spectroscopy data suggest that binding of compounds of both classes to K-Ras is accompanied by significant changes in protein secondary structure. In mice, inhibitors potently inhibited growth of H358 human lung tumor xenograft and Lewis lung carcinoma when injected subcutaneously every second day. The compounds are promising drug candidates for the treatment of many tumor types. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-426. doi:1538-7445.AM2012-LB-426
Processing and Storage of Viable Human Tissues
Authors: Henry Brown
Journal: JAMA (1967)

Organ-Transplantation, edited by Felix Largiadèr, 220 pp, 48 illus, 49 marks, $12.25, Stuttgart: Georg Thieme Verlag, 1966. Tissue Grafting and Radiation, by H. S. Micklem and John F. Loutit, with an appendix by Charles E. Ford (prepared under the direction of the American Institute of Biological Sciences for the Division of Technical Information, US Atomic Energy Commission), 288 pp, with illus, $7, New York and London: Academic Press, Inc., 1966. <i>Processing and Storage of Viable Human Tissues</i>is an excellent hand book, with good illustrations and text, offering practical methods and recipes for tissue preservation. There is a good section on cold preservation of tissues, nutrient storage media, variations in icecrystal formation and protective freezing of tissues with glycerol and dimethyl sulfoxide (DMSO). No mention is made of toxicity of glycerol at temperatures above freezing, or of possible hepatotoxicity of DMSO, or of the protective action of protein, usually albumin,
1064-180 Splenectomy and adoptive transfer of splenocytes reveal a critical role for spleen in mediating athero-protective effects of immunization with apolipoprotein B-100-related peptide sequence in apo E(- l -) mice
Authors: Kuang-Yuh Chyu, Stephanie M Babbidge, Paul C Dimayuga, Juliana Yano, Jan Nilsson, Bojan Cercek, Prediman K Shah, Gunilla Nordin Fredrikson
Journal: Journal of the American College of Cardiology (2004)
Role of the pituitary in tumor promotion with ethinyl estradiol in rat liver
Authors: I HALLSTROM
Journal: Hepatology (1996)

Synthetic estrogens act as tumor promoters in rat liver. Because estrogen treatment markedly increases the secretion of pituitary prolactin, also shown to be a tumor promoter in rat liver, the possibility of a pituitary influence in estrogen promotion was investigated in Wistar rats. In diethylnitrosamine (DEN)-initiated hypophysectomized (hx) female rats, 24 weeks of ethinyl estradiol (EE) administration (500 microg/kg/d, intraperitoneally) did not increase the number of hepatocyte nodules and did not induce hepatocellular carcinoma (HCC) in a 2-year study. Very few placental forms of glutathione-S-transferase (GST-P)-positive foci were observed at the end of EE administration. Estrogen receptor (ER) messenger RNA (mRNA) levels in hx females were 20% of the levels in intact females. EE administration (range, 160-210 microg/kg/d, subcutaneous release pellets) to DEN-initiated intact males and females increased the number and size of hepatocyte foci. A significant increase in HCC frequency was observed in EE-treated females compared with females receiving sham-release pellets, and the latency period for HCC induction was decreased by EE in both males and females. Inhibition of prolactin (PRL) secretion by bromocriptine (Brc) (ParlodelLAR, slow intramuscular release vehicles) during EE treatment decreased the number of foci without affecting their size and markedly prolonged the latency period in both sexes. EE treatment also significantly increased the expression of c-myc, and c-jun, enhanced the levels of growth hormone receptor (GHr) mRNA in females and the levels of ER mRNA in males and "feminized" the expression of the GH-regulated genes cytochrome P450 (CYP), 2C11, CYP 2C12, and GHr in male liver. Brc administration decreased the mRNA levels of the female-predominant CYP 2C12 in EE-treated males but otherwise had no effects. In conclusion, a decreased promotive effect of EE was obtained by decreasing the PRL levels, indicating that estrogens exert at least part of their promotion effects indirectly, by increasing the levels of pituitary PRL.
Sexual Transmission Efficiency of Hepatitis B Virus and Human Immunodeficiency Virus Among Homosexual Men
Authors: Lawrence A. Kingsley, Charles R. Rinaldo, David W. Lyter, Ronald O. Valdiserri, Steven H. Belle, Monto Ho
Journal: JAMA (1990)

The relative sexual transmission efficiency of hepatitis B virus (HBV) and human immunodeficiency virus type 1 (HIV-1) was investigated by a prospective study of homosexual men in Pittsburgh, Pa, from the Multicenter AIDS Cohort Study. During the 30-month follow-up, 19.8% and 7.8% of the initially seronegative HBV and HIV-1 groups were estimated to seroconvert to HBV and HIV-1, respectively. The significantly higher cumulative HBV seroconversion rate occurred despite a much lower prevalence of hepatitis B carriers (7% were hepatitis B surface antigen positive) compared with HIV-1 carriers (22% were HIV-1 antibody positive). The sexual exposure profile of HBV and HIV-1 seroconverters was similar during the 6 months prior to seroconversion, supporting the link between anal intercourse and acquisition of either infection. However, insertive, not receptive, anal intercourse was the major risk factor identified for HBV seroconversion, suggesting that transurethral exposure is an important mode of transmission. These data suggest that HBV is transmitted 8.6-fold more efficiently than HIV-1 among homosexual men studied and underscore the benefits of both HBV immunization and use of condoms during intercourse to prevent HBV infection. (<i>JAMA</i>. 1990;264:230-234)
More queries about H1N1 scandal
Authors: M. Girard
Journal: BMJ (2010)

Why did it take so long to detect the trick uncovered by the BMJ and Bureau of Investigative Journalism’s inquiry?1 In 1997, a Beecham’s business manager claimed: “We started increasing the awareness of the European experts of the World Health Organization about hepatitis B in 1988. From then to 1991, we financed epidemiological …
Poly(α-hydroxy acids): carriers for bone morphogenetic proteins
Authors: Jeffrey O. Hollinger, Kam Leong
Journal: Biomaterials (1996)

A broad spectrum of cells and cell products is associated with bone homeostasis and the renewal of bone following injury. The coupled interactions among cells provide the power behind sculpting of bone, sustaining form, and ensuring functionality. Local and systemic regulatory molecules (e.g. growth factors, hormones) direct cellular interactions through autocrine, paracrine and hormonal pathways. Recently, genes for a class of osteogenic regulatory molecules have been cloned, and gene product expression has enabled investigators to assess safety and efficacy in animal studies. The molecules are known as bone morphogenetic proteins (BMPs). Therapeutic applications of BMPs depend on a carrier system. A carrier could spatially and temporally localize BMP for regional needs and be custom-tailored for acute craniofacial applications or for recalcitrant extremity non-unions. The poly(α-hydroxy acids) (PHAs) may be suitable for these applications. Therefore, the purposes of this paper are (i) to mention, briefly, basic concepts of the bone wound continuum and the possible therapeutic roles of BMPs; (ii) to outline several properties of selected PHAs relevant to bone regeneration dynamics; and (iii) to review selected preclinical studies with PHAs.
Abstract 3280: Loss of the tumor suppressor APC in cells expressing lysozyme M results in murine endometrial hyperplasia
Authors: Susan M. Kitchen-Goosen, Sarah C. Sternberger, Arthur S. Alberts
Journal: Cancer Research (2012)

Abstract The Adenomatous polyposis coli (APC1) tumor suppressor is a multi-function protein that is involved in both the Wnt signaling cascade and cytoskeletal remodeling. Mutations or loss of APC1 can result in defects in cell migration, proliferation, and differentiation. APC frequently collaborates with the canonical Diaphanous-related formin, mDia1 (DIAPH1), which also functions to regulate cytoskeletal dynamics. APC1 and DIAPH1 are genetically linked on Chromosome 5q in a region frequently disrupted in myeloproliferative neoplasms (MPNs). Mice lacking mDia1 (Drf1) and the Apc min mice develop myelodysplastic phenotypes. The physical and functional linkage of APC and mDia1 as 5q tumor suppressors and in cytoskeletal remodeling led us to explore the role of APC in tumor suppression in myeloid-derived cell lineages. We created a mouse which lacks APC in myeloid lineage cells by breeding Apc-flox mice with mice expressing Cre recombinase under the control of lysozyme M (LyzsM) gene promoter. Lysozyme M is expressed in myeloid lineage cells including monocytes, macrophages and granulocytes. Surprisingly, the female mice develop cystic endometrial hyperplasia and are unable to sustain pregnancy. Lysozyme M expression appears to be limited to tissue resident macrophages within the uterus and was not detected in uterine epithelial cells. However, there is a small subset of uterine epithelial cells with increased β-catenin expression, suggesting that these cells lack APC. This subset of cells has elevated expression of cyclin D1, a regulator of cell cycle progression and a downstream effector of Wnt signaling, resulting in increased proliferation. Interestingly, the uterine epithelial cells with increased β-catenin expression also have increased estrogen receptor ≤ (ERα) expression. Estrogen stimulates uterine growth and unopposed estrogen signaling is a hallmark of Type I endometrial cancer. It is unclear if the endometrial hyperplasia seen in these mice is due to lysozyme M expression early on in uterine epithelial cell development or perhaps in a progenitor cell population. A second alternative is that loss of APC in tissue resident myeloid cells residing in the uterine stroma affects epithelial morphology. Regardless, these data suggest that APC plays a role in uterine tissue homeostasis, perhaps even regulating ERα expression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3280. doi:1538-7445.AM2012-3280
Data on births by ethnic group now available for England and Wales
Authors: K. A Moser, N. Dattani, D. A Leon, K. M Stanfield
Journal: BMJ (2008)

Raleigh says that ethnic origin is not known for sentinel outcomes—such as the 636 000 births and 470 000 deaths annually in England.1 However, we have just published data by ethnic group on all births in England and Wales in 2005.2 Like the …
Modulation of Coreceptor Transcription during Positive Selection Dictates Lineage Fate Independently of TCR/Coreceptor Specificity
Authors: Sophia D. Sarafova, Batu Erman, Qing Yu, François Van Laethem, Terry Guinter, Susan O. Sharrow, Lionel Feigenbaum, Kathryn F. Wildt, Wilfried Ellmeier, Alfred Singer
Journal: Immunity (2005)
Abnormalities of Fatty Acid Oxidation
Authors: William L. Nyhan
Journal: New England Journal of Medicine (1988)

Inborn errors involving the oxidative metabolism of fatty acids represent a newly recognized area of human disease. Despite their recent discovery, these disorders in the aggregate appear to be relatively common. Their clinical presentation may be misleading, and definitive diagnosis difficult. Yet, they can lead to substantial morbidity and mortality. In this issue of the Journal, there are two important contributions to this emerging field.1 , 2 The classic presentation of systemic abnormalities of fatty acid oxidation includes hypoketotic hypoglycemia. Acute episodes of vomiting and lethargy may occur, often after fasting induced by intercurrent illness, and may progress to coma.3 Understandably, . . .
EXTENSIVE AVULSION OF SCALP.REPORT OF A CASE TREATED BY PLASTIC REPAIR AND FOLLOWED BY TETANUS WITH RECOVERY.
Authors: H. A. HAUBOLD
Journal: JAMA (1907)

The case forming the text of the following communication illustrates certain points in the treatment of conditions which, while not frequently met, may and do occur in the practice of most surgeons, and, although no new principle is submitted here, the application of accepted ones deserves mention. Following so closely on the excellent summary<sup>1</sup>of the treatment of tetanus with serum by Jacobson of Syracuse and Pease of Albany, a discussion of greater length in this connection would burden unnecessarily the literature and serve no useful purpose. In looking over the cases forming the basis of Jacobson's and Pease's work, it would appear that they, like all of us who compile and deduce from the publications of others, were confronted with the fact that most important details are lacking in the reports of cases submitted by the various authors, and if this contribution seems somewhat protracted it must be
Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.
Authors: M Sato, W Grasser, N Endo, R Akins, H Simmons, D D Thompson, E Golub, G A Rodan
Journal: Journal of Clinical Investigation (1991)

Studies of the mode of action of the bisphosphonate alendronate showed that 1 d after the injection of 0.4 mg/kg [3H]alendronate to newborn rats, 72% of the osteoclastic surface, 2% of the bone forming, and 13% of all other surfaces were densely labeled. Silver grains were seen above the osteoclasts and no other cells. 6 d later the label was 600-1,000 microns away from the epiphyseal plate and buried inside the bone, indicating normal growth and matrix deposition on top of alendronate-containing bone. Osteoclasts from adult animals, infused with parathyroid hormone-related peptide (1-34) and treated with 0.4 mg/kg alendronate subcutaneously for 2 d, all lacked ruffled border but not clear zone. In vitro alendronate bound to bone particles with a Kd of approximately 1 mM and a capacity of 100 nmol/mg at pH 7. At pH 3.5 binding was reduced by 50%. Alendronate inhibited bone resorption by isolated chicken or rat osteoclasts when the amount on the bone surface was around 1.3 x 10(-3) fmol/microns 2, which would produce a concentration of 0.1-1 mM in the resorption space if 50% were released. At these concentrations membrane leakiness to calcium was observed. These findings suggest that alendronate binds to resorption surfaces, is locally released during acidification, the rise in concentration stops resorption and membrane ruffling, without destroying the osteoclasts.
Comments on extrapolation of cancer response from high dose to low dose.
Authors: N Nelson
Journal: Environmental Health Perspectives (1978)

In making judgments as to the cancer risk from low level exposure to carcinogens it is generally necessary to base these judgments on high dose or high incidence data from laboratory or epidemiological studies. The biological considerations involved in making such extrapolations are discussed, as well as some of the mathematical procedures. The difficulties presented by moving from species to species, or from differently acting carcinogenic agents is considered.
X Chromosome Errors in Female Criminals
Authors: Mary A. Telfer
Journal: JAMA (1968)

<h3>To the Editor:—</h3> Since W. M. Court Brown<sup>1</sup>first raised the broad question of whether individuals with abnormal sex-chromosome complements "could be held in law to suffer from diminished responsibility," much attention, both lay (<i>New York Times</i>, April 21, 1968) and scientific,<sup>2</sup>has been accorded the legal status of criminal XXY and XYY males. We are not aware that the same question has been asked with explicit reference to criminal females; we would like to ask it and to demonstrate its relevance. In Pennsylvania correctional institutions for women, we have recently performed buccal smears on 117 juvenile delinquents, confined largely for chronic truancy, and 133 adults incarcerated for more serious offenses including murder, larceny, and burglary. Only one abnormality was found; among the adults, a 22-year-old woman held as an incorrigible, guilty of defiant behavior and prison breach, repeatedly gave buccal smears containing nuclei displaying two, and occasionally
Improved myocardial capillarisation in spontaneously hypertensive rats treated with nifedipine
Authors: Z. TUREK, K. KUBAT, S. KAZDA, L. HOOFD, K. RAKUSAN
Journal: Cardiovascular Research (1987)

Journal Article Improved myocardial capillarisation in spontaneously hypertensive rats treated with nifedipine Get access ZDENEK TUREK, ZDENEK TUREK **From the Department of Physiology, Catholic University, Nijmegen, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar KAREL KUBAT, KAREL KUBAT †From the Department of Pathological Anatomy, Faculty of Medicine, Catholic University, Nijmegen, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar STANISLAV KAZDA, STANISLAV KAZDA ‡From the Institute of Pharmacology, Bayer AG, Wuppertal, Federal Republic of Germany Search for other works by this author on: Oxford Academic PubMed Google Scholar LOUIS HOOFD, LOUIS HOOFD **From the Department of Physiology, Catholic University, Nijmegen, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar KAREL RAKUSAN KAREL RAKUSAN §Department of Physiology, School of Medicine, University of Ottawa, Ottawa, Ontario, Canada. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 21, Issue 10, October 1987, Pages 725–729, https://doi.org/10.1093/cvr/21.10.725 Published: 01 October 1987 Article history Received: 03 September 1986 Accepted: 30 April 1987 Published: 01 October 1987
Gastroenterology and Hepatology
Authors: William D. Carey
Journal: JAMA (1991)

Pharmacotherapy for gastroesophageal reflux disease is needed when simple measures fail. Antacids, H<sub>2</sub>blockers, sucralfate, and (occasionally) metaclopramide may be effective. Treatment failures may respond to omeprazole (Prilosec), a recently released agent that blocks hydrogen ion secretion by the gastric parietal cells. It is the most potent acid-suppressing agent available and is unsurpassed in its ability to provide symptomatic control and promote esophageal mucosal healing (80% to 86% at 6 weeks, &gt;90% at 12 weeks). Since this agent is approved for use for only 8 weeks of therapy, both physician and patient face a dilemma of what to do next in managing this chronic disease. Omeprazole also represents an advance in healing rates for both gastric and duodenal ulcers. Two weeks of therapy may be adequate. Compared with ranitidine, omeprazole had a 17% higher healing rate after 2 weeks of therapy (79% vs 62%). The healing rate after 4
LIGHT SENSITIVE DERMATOSES
Authors: NELSON PAUL ANDERSON
Journal: JAMA (1934)

The problem of light sensitivity is one in which the final solution will probably be found by the biochemist. It appears to be bound inseparably with sulphur metabolism, and through sulphur metabolism with the amino acids and perhaps also the vitamins. A review of some of the recent work on sulphur metabolism is certainly pertinent to the question of light sensitivity. Harris and Hoyt<sup>1</sup>subjected paramecia to the effect of ultraviolet rays that had previously passed through a solution of cystinein sodium hydroxide. They found that the time of exposure required to produce fatal results was 1,200 seconds if the ultraviolet rays first passed through the cystine solution, as compared with 150 seconds in the controls. From this they argued that the susceptibility of protoplasm to ultraviolet radiation was conditioned by the selective absorption of the toxic rays by cystine and certain aromatic amino acids. Confirmation of this